IL151981A0 - Method of treating hepatitis delta viral infection - Google Patents
Method of treating hepatitis delta viral infectionInfo
- Publication number
- IL151981A0 IL151981A0 IL15198101A IL15198101A IL151981A0 IL 151981 A0 IL151981 A0 IL 151981A0 IL 15198101 A IL15198101 A IL 15198101A IL 15198101 A IL15198101 A IL 15198101A IL 151981 A0 IL151981 A0 IL 151981A0
- Authority
- IL
- Israel
- Prior art keywords
- hepatitis delta
- viral infection
- treating hepatitis
- nucleoside
- vivo
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5765—Hepatitis delta antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19313500P | 2000-03-29 | 2000-03-29 | |
PCT/US2001/009987 WO2001072294A2 (en) | 2000-03-29 | 2001-03-29 | Method of treating hepatitis delta viral infection |
Publications (1)
Publication Number | Publication Date |
---|---|
IL151981A0 true IL151981A0 (en) | 2003-04-10 |
Family
ID=22712393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15198101A IL151981A0 (en) | 2000-03-29 | 2001-03-29 | Method of treating hepatitis delta viral infection |
Country Status (16)
Country | Link |
---|---|
US (2) | US6670342B2 (es) |
EP (1) | EP1284720B1 (es) |
JP (1) | JP2003528138A (es) |
KR (3) | KR20080059679A (es) |
CN (1) | CN1268345C (es) |
AT (1) | ATE339211T1 (es) |
AU (1) | AU2001249564A1 (es) |
BR (1) | BR0109716A (es) |
CA (1) | CA2405502A1 (es) |
CY (1) | CY1105768T1 (es) |
DE (1) | DE60123042T2 (es) |
DK (1) | DK1284720T3 (es) |
ES (1) | ES2272460T3 (es) |
IL (1) | IL151981A0 (es) |
PT (1) | PT1284720E (es) |
WO (1) | WO2001072294A2 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080059679A (ko) | 2000-03-29 | 2008-06-30 | 조지타운 유니버시티 | 델타형 간염 바이러스 감염의 치료방법 |
US6787526B1 (en) | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
DE10346721A1 (de) * | 2003-10-08 | 2005-05-04 | Holger Kalthoff | Oligonukleotide, diese enthaltende Mittel und deren Verwendung |
WO2010090723A2 (en) * | 2009-02-04 | 2010-08-12 | University Of Georgia Research Foundation, Inc. | Methods of inhibiting fibrogenesis and treating fibrotic disease |
EA201270632A1 (ru) * | 2009-11-16 | 2013-01-30 | Юниверсити Оф Джорджия Рисерч Фаундейшн, Инк. | 2'-фтор-6'-метилен карбоциклические нуклеозиды и способы лечения вирусных инфекций |
US8816074B2 (en) | 2009-11-16 | 2014-08-26 | University of Georgia Foundation, Inc. | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections |
IN2015DN01087A (es) | 2012-08-30 | 2015-06-26 | Replicor Inc | |
EA039949B1 (ru) * | 2012-09-21 | 2022-03-31 | Репликор Инк. | Способы лечения инфекций вирусом гепатита в и гепатита d |
US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
WO2016090107A2 (en) * | 2014-12-04 | 2016-06-09 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
CN104694544A (zh) * | 2015-03-24 | 2015-06-10 | 刘红卫 | 结合丁型肝炎病毒的核酸适配子及其应用 |
WO2016164619A2 (en) * | 2015-04-07 | 2016-10-13 | Spring Bank Pharmaceuticals, Inc. | Compositions and methods for the treatment of hbv infection |
EP3285768B1 (en) | 2015-04-21 | 2020-12-30 | Eiger Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising lonafarnib and ritonavir |
WO2017132332A1 (en) * | 2016-01-28 | 2017-08-03 | Svenska Vaccinfabriken Produktion Ab | Chimeric hepatitis d virus antigen and hepatitis b virus pre s1 genes for use alone or in vaccines contaning hepatitis b virus genes |
CN106333960A (zh) * | 2016-11-01 | 2017-01-18 | 侯建生 | 臭氧化油在肝病防治中的应用 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4211771A (en) | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
US4093714A (en) | 1974-03-15 | 1978-06-06 | Icn Pharmaceuticals, Inc. | 9β-D-Arabinofuranosylpurine nucleotides and method of use |
US4210638A (en) | 1978-03-17 | 1980-07-01 | Pcr, Inc. | Antiviral composition and method of treating virus diseases |
GB2060604B (en) | 1979-10-03 | 1983-11-23 | Univ Birmingham And Stichting | E15-(2-halogenovinyl)-2'-deoxycytidines |
US4468384A (en) | 1982-01-05 | 1984-08-28 | The Research Foundation Of State University Of New York | Method for the inhibition of the replication of DNA viruses with 5-substituted 2-pyrimidinone nucleosides |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
DE3479158D1 (en) | 1983-03-04 | 1989-08-31 | Noctech Ltd | Diagnostic agent, a process for its preparation and its use in diagnostic methods |
US4666892A (en) | 1984-03-06 | 1987-05-19 | Sloan-Kettering Memorial Cancer Center | Method and composition for hepatitis treatment with pyrimidine nucleoside compounds |
US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
CA1338800C (en) | 1986-06-17 | 1996-12-17 | Michael Houghton | Hepatitis delta and diagnostics and vaccines |
US5246924A (en) * | 1987-09-03 | 1993-09-21 | Sloan-Kettering Institute For Cancer Research | Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil |
JPH03501253A (ja) | 1987-09-22 | 1991-03-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | エイズ(aids)治療を目的とするリポソームによるヌクレオシド類似物質 |
US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
US5463092A (en) | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
AU7872491A (en) | 1990-05-07 | 1991-11-27 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
EP0531452A4 (en) | 1990-05-29 | 1993-06-09 | Vical, Inc. | Synthesis of glycerol di- and triphosphate derivatives |
ES2083580T3 (es) | 1990-06-13 | 1996-04-16 | Arnold Glazier | Profarmacos de fosforo. |
US5256641A (en) | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5149794A (en) | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
US5543389A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
EP0491077A1 (en) | 1990-12-19 | 1992-06-24 | Medeva Holdings B.V. | A composition used as a therapeutic agent against chronic viral hepatic diseases |
GB9110874D0 (en) | 1991-05-20 | 1991-07-10 | Iaf Biochem Int | Medicaments |
JPH07500573A (ja) | 1991-07-12 | 1995-01-19 | ネクススター・ファーマシューティカルズ・インコーポレイテッド | 抗ウィルス性リポヌクレオシド:b型肝炎の治療 |
US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
GB9116601D0 (en) | 1991-08-01 | 1991-09-18 | Iaf Biochem Int | 1,3-oxathiolane nucleoside analogues |
WO1994026273A1 (en) | 1993-05-12 | 1994-11-24 | Hostetler Karl Y | Acyclovir derivatives for topical use |
WO1994028908A2 (en) | 1993-06-10 | 1994-12-22 | Wake Forest University | (phospho)lipids for combatting hepatitis b virus infection |
US5587362A (en) | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
US5639647A (en) | 1994-03-29 | 1997-06-17 | Ribozyme Pharmaceuticals, Inc. | 2'-deoxy-2'alkylnucleotide containing nucleic acid |
US5646262A (en) | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
US5696277A (en) | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
US5808040A (en) | 1995-01-30 | 1998-09-15 | Yale University | L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides |
GB9505025D0 (en) | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
US5985662A (en) | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
AU6605196A (en) * | 1996-02-29 | 1997-09-16 | Duke University | Method of treating hepatitis delta virus infection |
US5753789A (en) | 1996-07-26 | 1998-05-19 | Yale University | Oligonucleotides containing L-nucleosides |
DE19641034A1 (de) | 1996-10-04 | 1998-04-09 | Claussen Nils | Pulverförmige Zubereitung von wasserempfindlichen anorganischen Substanzen, ihre Herstellung und Verwendung |
KR20080059679A (ko) * | 2000-03-29 | 2008-06-30 | 조지타운 유니버시티 | 델타형 간염 바이러스 감염의 치료방법 |
US6985662B2 (en) * | 2003-10-30 | 2006-01-10 | Corning Incorporated | Dispersion compensating fiber for moderate dispersion NZDSF and transmission system utilizing same |
-
2001
- 2001-03-29 KR KR1020087014186A patent/KR20080059679A/ko not_active Application Discontinuation
- 2001-03-29 AT AT01922803T patent/ATE339211T1/de not_active IP Right Cessation
- 2001-03-29 US US09/821,278 patent/US6670342B2/en not_active Expired - Lifetime
- 2001-03-29 DK DK01922803T patent/DK1284720T3/da active
- 2001-03-29 JP JP2001570255A patent/JP2003528138A/ja not_active Withdrawn
- 2001-03-29 DE DE60123042T patent/DE60123042T2/de not_active Expired - Lifetime
- 2001-03-29 ES ES01922803T patent/ES2272460T3/es not_active Expired - Lifetime
- 2001-03-29 CA CA002405502A patent/CA2405502A1/en not_active Abandoned
- 2001-03-29 PT PT01922803T patent/PT1284720E/pt unknown
- 2001-03-29 EP EP01922803A patent/EP1284720B1/en not_active Expired - Lifetime
- 2001-03-29 CN CNB018104134A patent/CN1268345C/zh not_active Expired - Fee Related
- 2001-03-29 AU AU2001249564A patent/AU2001249564A1/en not_active Abandoned
- 2001-03-29 KR KR1020027012957A patent/KR100893549B1/ko not_active IP Right Cessation
- 2001-03-29 WO PCT/US2001/009987 patent/WO2001072294A2/en active IP Right Grant
- 2001-03-29 IL IL15198101A patent/IL151981A0/xx unknown
- 2001-03-29 BR BR0109716-4A patent/BR0109716A/pt not_active Application Discontinuation
- 2001-03-29 KR KR1020087030736A patent/KR20090006230A/ko not_active Application Discontinuation
-
2002
- 2002-11-22 US US10/302,814 patent/US7511027B2/en not_active Expired - Fee Related
-
2006
- 2006-11-09 CY CY20061101613T patent/CY1105768T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
KR100893549B1 (ko) | 2009-04-17 |
WO2001072294A3 (en) | 2002-05-23 |
US20020160980A1 (en) | 2002-10-31 |
DK1284720T3 (da) | 2007-01-15 |
ATE339211T1 (de) | 2006-10-15 |
US20030158149A1 (en) | 2003-08-21 |
PT1284720E (pt) | 2006-12-29 |
AU2001249564A1 (en) | 2001-10-08 |
US7511027B2 (en) | 2009-03-31 |
DE60123042T2 (de) | 2007-04-12 |
CN1268345C (zh) | 2006-08-09 |
CN1431907A (zh) | 2003-07-23 |
CY1105768T1 (el) | 2011-02-02 |
EP1284720B1 (en) | 2006-09-13 |
KR20030031472A (ko) | 2003-04-21 |
EP1284720A2 (en) | 2003-02-26 |
BR0109716A (pt) | 2003-06-17 |
US6670342B2 (en) | 2003-12-30 |
KR20080059679A (ko) | 2008-06-30 |
DE60123042D1 (de) | 2006-10-26 |
KR20090006230A (ko) | 2009-01-14 |
CA2405502A1 (en) | 2001-10-04 |
ES2272460T3 (es) | 2007-05-01 |
JP2003528138A (ja) | 2003-09-24 |
WO2001072294A2 (en) | 2001-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU92102A (sh) | Metode i smeše za lečenje virusnog hepatitisa c | |
IL151981A0 (en) | Method of treating hepatitis delta viral infection | |
IL153078A0 (en) | Methods for treating hepatitis delta virus infection with beta-l-2' deoxy nucleosides | |
AP1771A (en) | 3'-Prodrugs of 2'-deoxy-?-L-nucleosides. | |
WO2003026589A3 (en) | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides | |
IL193148A0 (en) | Use of combinations of agents for the preparation of medicaments for treatment of hepatitis b virus | |
HK1041215A1 (en) | Use of thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir in manufacturing pharmaceutical combination preparations for treating hepatitis b infection. | |
AU8353601A (en) | Treatment of hepatitis c with thymosin, interferon and ribavirin | |
HK1039935A1 (en) | Use of (1r, 4s)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol in hbv | |
RS20120367A3 (en) | METHODS AND MIXTURES FOR TREATMENT OF VIRAL HEPATITIS C | |
AU8716001A (en) | Treatment of hepatitis c with thymosin and pegylated interferon |